Creative Medical Technology Holdings Inc (CELZ) Stock AnalysisCELZStock AnalysisCreative Medical Technology Holdings Inc

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Creative Medical Technology Holdings Inc (CELZ) is currently not a strong buy due to its recent performance and financial instability. The stock has a current price of $1.14, which is significantly lower than the analyst price target of $20, indicating potential upside. However, the stock has seen a 12.98% decline over the past five days and a staggering 64.49% drop over the past year, raising concerns about its stability. Additionally, the company reported a negative gross margin of -1037.66% in Q3 2024, which highlights ongoing financial challenges. The main risk is the company's negative earnings per share (EPS) of -0.41 reported in the last earnings, indicating continued losses. Therefore, while there is potential for recovery, the current financial indicators suggest a cautious approach is warranted.